Our current GC/MS protocol can not distinguish between metamizole and 4-methylaminoantipyrine. 4-Methylaminoantipyrine is a metabolite of metamizole. Their mass spectra are indistinguishable because metamizole undergoes thermal decomposition to 4-methylaminoantipyrine and aminopyrine during GC-MS analysis. The chemical identified in this sample could be either Metamizole or 4-Methylaminoantipyrine, or a combination of the two.
Jul 7, 2021: Identification of Metamizole changed to Metamizole OR 4-Methylaminoantipyrine.
Send in a sample for testing
DrugsData tests all psychoactive drugs including ecstasy tablets, powders, research chemicals, novel pschoactive substances, and other drugs through our DEA-licensed laboratory. Ecstasy/Molly tablets cost $100. Recreational drug powder/crystal/blotter costs $100. Pharmaceuticals, supplements and all others cost $150 per analysis.
Should the public have access to independent analysis of the products they consume?
The vast majority of analyses of over-the-counter, prescription, and recreational drugs are performed in secret with no independent oversite or review. No other historical record, free from politically-controlled agencies, is currently available in North America nor most other parts of the world.
DrugsData, a project of Erowid Center, needs the support of professionals, students, parents, individuals with means, and small foundations for a total yearly budget of around $120,000 USD. Erowid Center's general budget and the co-pays we require fund most of this cost.
Regarding Metamizole / 4-Methylaminoantipyrine:
Our current GC/MS protocol can not distinguish between metamizole and 4-methylaminoantipyrine. 4-Methylaminoantipyrine is a metabolite of metamizole. Their mass spectra are indistinguishable because metamizole undergoes thermal decomposition to 4-methylaminoantipyrine and aminopyrine during GC-MS analysis. The chemical identified in this sample could be either Metamizole or 4-Methylaminoantipyrine, or a combination of the two.